Drug intelligence / Profile preview

propofol + cisatracurium

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Intravenous

Overview

Propofol + cisatracurium is a combination of two separate medications used together in anesthesia protocols. Propofol is an intravenous anesthetic agent used for induction and maintenance of general anesthesia, while cisatracurium is a non-depolarizing neuromuscular blocking drug that facilitates tracheal intubation and provides skeletal muscle relaxation during surgery. When used together, propofol induces unconsciousness while cisatracurium provides muscle relaxation. These medications should not be mixed in the same syringe or administered simultaneously through the same needle.

Targets

Muscle-type nicotinic acetylcholine receptorGABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on propofol + cisatracurium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on propofol + cisatracurium.

Explore the full profile